Galactooligosaccharides / RP-G28

ID: galactooligosaccharides_rpg28

Aliases: GOS, beta-GOS, RP-G28, galacto-oligosaccharide

Type: compound

Route/form: oral prebiotic oligosaccharide

Status: investigational_or_supplement

Evidence level: human RCT

Best data tier: human controlled/review

Support scope: human, review/regulatory

Source types: human_rct, human_trial, review

Linked sources: 4

Broad outcomes: Gut / immune / inflammation

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• prebiotic lactose-fermenting bacteria enrichment
• Bifidobacterium and Lactobacillus support
• colonic adaptation to lactose

Optimization domains

• gut health
• microbiome
• lactose tolerance
• prebiotic
• GI

Research basis

• Randomized human RP-G28 trials tested a defined galacto-oligosaccharide approach for lactose intolerance, with microbiome changes and symptom/tolerance endpoints.
• Daily lactose-feeding work supports the broader idea that colonic microbial adaptation can alter lactose-tolerance symptoms in some lactose maldigesters.

Limits, risks, and missing evidence

• A microbiome-adaptation strategy is not the same as restoring intestinal lactase persistence.
• GOS can worsen gas, bloating, or FODMAP-type symptoms in some people, and RP-G28 development history includes mixed clinical-commercial outcomes.

Risk flags

• GI tolerability
• FODMAP context
• not lactase replacement
• product specific evidence
• mixed development history

Linked papers, labels, and reviews

1. Improving lactose digestion and symptoms of lactose intolerance with a novel galacto-oligosaccharide (RP-G28): a randomized, double-blind clinical trial
   human_rct / pubmed_rpg28_lactose_rct_2013
   Randomized double-blind RP-G28 trial using hydrogen breath testing and lactose-intolerance symptom endpoints.
2. Galacto-Oligosaccharide RP-G28 Improves Multiple Clinical Outcomes in Lactose-Intolerant Patients
   human_rct / pubmed_rpg28_multiple_outcomes_2020
   Multicenter blinded placebo-controlled RP-G28 study reporting clinical outcomes and fecal microbiome changes including Bifidobacterium.
3. Colonic adaptation to daily lactose feeding in lactose maldigesters reduces lactose intolerance
   human_trial / pubmed_colonic_adaptation_lactose_1996
   Blinded crossover human work supporting the concept of microbial/colonic adaptation to repeated lactose exposure.
4. Adaptation to Lactose in Lactase Non Persistent People: Effects on Intolerance and the Relationship between Dairy Food Consumption and Evaluation of Diseases
   review / pubmed_lactose_adaptation_review_2015
   Review source for lactase non-persistence, dairy exposure, and colonic adaptation mechanisms.